248 related articles for article (PubMed ID: 33910926)
1. Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression.
Saghafinia S; Homicsko K; Di Domenico A; Wullschleger S; Perren A; Marinoni I; Ciriello G; Michael IP; Hanahan D
Cancer Discov; 2021 Oct; 11(10):2638-2657. PubMed ID: 33910926
[TBL] [Abstract][Full Text] [Related]
2. A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics.
Sadanandam A; Wullschleger S; Lyssiotis CA; Grötzinger C; Barbi S; Bersani S; Körner J; Wafy I; Mafficini A; Lawlor RT; Simbolo M; Asara JM; Bläker H; Cantley LC; Wiedenmann B; Scarpa A; Hanahan D
Cancer Discov; 2015 Dec; 5(12):1296-313. PubMed ID: 26446169
[TBL] [Abstract][Full Text] [Related]
3. Rb and p53 Execute Distinct Roles in the Development of Pancreatic Neuroendocrine Tumors.
Yamauchi Y; Kodama Y; Shiokawa M; Kakiuchi N; Marui S; Kuwada T; Sogabe Y; Tomono T; Mima A; Morita T; Matsumori T; Ueda T; Tsuda M; Nishikawa Y; Kuriyama K; Sakuma Y; Ota Y; Maruno T; Uza N; Masuda A; Tatsuoka H; Yabe D; Minamiguchi S; Masui T; Inagaki N; Uemoto S; Chiba T; Seno H
Cancer Res; 2020 Sep; 80(17):3620-3630. PubMed ID: 32591410
[TBL] [Abstract][Full Text] [Related]
4. A set of microRNAs coordinately controls tumorigenesis, invasion, and metastasis.
Michael IP; Saghafinia S; Hanahan D
Proc Natl Acad Sci U S A; 2019 Nov; 116(48):24184-24195. PubMed ID: 31704767
[TBL] [Abstract][Full Text] [Related]
5. Cross-talk among MEN1, p53 and Notch regulates the proliferation of pancreatic neuroendocrine tumor cells by modulating INSM1 expression and subcellular localization.
Capodanno Y; Chen Y; Schrader J; Tomosugi M; Sumi S; Yokoyama A; Hiraoka N; Ohki R
Neoplasia; 2021 Sep; 23(9):979-992. PubMed ID: 34352404
[TBL] [Abstract][Full Text] [Related]
6. p53 and p16
Azzopardi S; Pang S; Klimstra DS; Du YN
Neoplasia; 2016 Oct; 18(10):610-617. PubMed ID: 27664376
[TBL] [Abstract][Full Text] [Related]
7. Placenta-Specific 8 Is Overexpressed and Regulates Cell Proliferation in Low-Grade Human Pancreatic Neuroendocrine Tumors.
Tatura M; Schmidt H; Haijat M; Stark M; Rinke A; Diels R; Lawlor RT; Scarpa A; Schrader J; Hackert T; Schimmack S; Gress TM; Buchholz M
Neuroendocrinology; 2020; 110(1-2):23-34. PubMed ID: 31018208
[TBL] [Abstract][Full Text] [Related]
8. Progranulin Stimulates Proliferation of Mouse Pancreatic Islet Cells and Is Overexpressed in the Endocrine Pancreatic Tissue of an MEN1 Mouse Model.
Barbu A; Lejonklou MH; Skogseid B
Pancreas; 2016 Apr; 45(4):533-40. PubMed ID: 26495792
[TBL] [Abstract][Full Text] [Related]
9. Functional malignant cell heterogeneity in pancreatic neuroendocrine tumors revealed by targeting of PDGF-DD.
Cortez E; Gladh H; Braun S; Bocci M; Cordero E; Björkström NK; Miyazaki H; Michael IP; Eriksson U; Folestad E; Pietras K
Proc Natl Acad Sci U S A; 2016 Feb; 113(7):E864-73. PubMed ID: 26831065
[TBL] [Abstract][Full Text] [Related]
10. Genetics of pancreatic neuroendocrine tumors: implications for the clinic.
Pea A; Hruban RH; Wood LD
Expert Rev Gastroenterol Hepatol; 2015; 9(11):1407-19. PubMed ID: 26413978
[TBL] [Abstract][Full Text] [Related]
11. Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?
Luchini C; Lawlor RT; Bersani S; Vicentini C; Paolino G; Mattiolo P; Pea A; Cingarlini S; Milella M; Scarpa A
Curr Oncol Rep; 2021 Jul; 23(9):106. PubMed ID: 34269919
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic Neuroendocrine Tumors in Mice Deficient in Proglucagon-Derived Peptides.
Takano Y; Kasai K; Takagishi Y; Kikumori T; Imai T; Murata Y; Hayashi Y
PLoS One; 2015; 10(7):e0133812. PubMed ID: 26192435
[TBL] [Abstract][Full Text] [Related]
13. A vicious partnership between AKT and PHLDA3 to facilitate neuroendocrine tumors.
Takikawa M; Ohki R
Cancer Sci; 2017 Jun; 108(6):1101-1108. PubMed ID: 28295876
[TBL] [Abstract][Full Text] [Related]
14. A Comprehensive Molecular Characterization of the Pancreatic Neuroendocrine Tumor Cell Lines BON-1 and QGP-1.
Luley KB; Biedermann SB; Künstner A; Busch H; Franzenburg S; Schrader J; Grabowski P; Wellner UF; Keck T; Brabant G; Schmid SM; Lehnert H; Ungefroren H
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32183367
[TBL] [Abstract][Full Text] [Related]
15. Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patients.
Speisky D; Duces A; Bièche I; Rebours V; Hammel P; Sauvanet A; Richard S; Bedossa P; Vidaud M; Murat A; Niccoli P; Scoazec JY; Ruszniewski P; Couvelard A;
Clin Cancer Res; 2012 May; 18(10):2838-49. PubMed ID: 22461457
[TBL] [Abstract][Full Text] [Related]
16. Genetic ablation of Bcl-x attenuates invasiveness without affecting apoptosis or tumor growth in a mouse model of pancreatic neuroendocrine cancer.
Hager JH; Ulanet DB; Hennighausen L; Hanahan D
PLoS One; 2009; 4(2):e4455. PubMed ID: 19209227
[TBL] [Abstract][Full Text] [Related]
17. Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors.
Chatani PD; Agarwal SK; Sadowski SM
Front Endocrinol (Lausanne); 2020; 11():575620. PubMed ID: 33537001
[TBL] [Abstract][Full Text] [Related]
18. Kmt2a cooperates with menin to suppress tumorigenesis in mouse pancreatic islets.
Lin W; Francis JM; Li H; Gao X; Pedamallu CS; Ernst P; Meyerson M
Cancer Biol Ther; 2016 Dec; 17(12):1274-1281. PubMed ID: 27801610
[TBL] [Abstract][Full Text] [Related]
19. The matricellular protein CYR61 interferes with normal pancreatic islets architecture and promotes pancreatic neuroendocrine tumor progression.
Huang YT; Lan Q; Ponsonnet L; Blanquet M; Christofori G; Zaric J; Rüegg C
Oncotarget; 2016 Jan; 7(2):1663-74. PubMed ID: 26625209
[TBL] [Abstract][Full Text] [Related]
20. Animal models and cell lines of pancreatic neuroendocrine tumors.
Babu V; Paul N; Yu R
Pancreas; 2013 Aug; 42(6):912-23. PubMed ID: 23851429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
